Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03329846 · ClinicalTrials.gov registry record · Phase 3
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT03329846 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 20 participants.
The verdict
NCT03329846, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated
Interventions
- DRUG Placebo
- BIOLOGICAL Nivolumab
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-11-30 |
| Est. Completion | 2020-07-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03329846
The ClinicalTrials.gov registry entry for NCT03329846 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03329846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03329846 about?
NCT03329846 is a clinical study titled "An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma". The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated
What is the current status of trial NCT03329846?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2017-11-30. Estimated completion is 2020-07-02.
What interventions are being tested in trial NCT03329846?
The interventions under investigation include: Placebo (DRUG), Nivolumab (BIOLOGICAL), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT03329846?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.